血嗜酸性粒细胞指导COPD急性加重口服泼尼松龙:STARR2非劣效随机试验
STARR2是在英国14家基层诊所开展的多中心、双盲、安慰剂对照、随机非劣效试验,纳入≥40岁、吸烟≥10包年、有COPD诊断且过去12个月至少1次需全身糖皮质激素的急性加重史成人。比较血嗜酸性粒细胞指导治疗(BET,嗜酸性粒细胞≥2%用泼尼松龙30 mg每日一次,<2%用安慰剂)与标准治疗(ST,均用泼尼松龙30 mg每日一次),疗程14天,均用抗生素。
要点
- 血嗜酸性粒细胞指导泼尼松龙治疗在COPD急性加重30天治疗失败率上非劣于标准治疗。
- 两组不良事件频率相似,最常见为糖尿和COPD急性加重住院,研究期间无死亡。
核心结论
- 在COPD急性加重时,血嗜酸性粒细胞指导的口服泼尼松龙治疗非劣于标准治疗,可安全减少全身糖皮质激素使用。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,在英国14家基层诊所开展,共招募308名参与者。
- 参与者按1:1随机分配至BET组(嗜酸性粒细胞≥2%用泼尼松龙30 mg每日一次,<2%用安慰剂)或ST组(均用泼尼松龙30 mg每日一次),疗程14天,均用抗生素。
- 主要结局为30天治疗失败率(需再次抗生素或激素、任何原因住院或死亡),在改良意向治疗人群分析;允许再次随机化,每人最多4次急性加重。
主要发现
- 非劣效分析支持BET非劣于ST。
- 不良事件频率两组相似,BET组糖尿2/102(2%)、ST组1/101(1%);COPD急性加重住院BET组2/102(2%)、ST组1/101(1%)。
- 研究期间无死亡。
关键数值与推荐
- BET组:点征血嗜酸性粒细胞≥2%时口服泼尼松龙30 mg每日一次,<2%时用安慰剂,疗程14天。
- ST组:无论嗜酸性粒细胞结果如何,均口服泼尼松龙30 mg每日一次,疗程14天。
- 所有患者均接受抗生素治疗。
临床怎么用
- 在基层医疗中,对COPD急性加重患者可依据血嗜酸性粒细胞计数决定是否使用口服泼尼松龙,以安全减少全身糖皮质激素暴露。
- 嗜酸性粒细胞≥2%者使用泼尼松龙30 mg每日一次,<2%者可不用泼尼松龙,均需联合抗生素。
局限性
- 研究预设为优效性试验,数据锁定前因随机化代码错误转为非劣效性。
- 研究在基层诊所开展,结果外推至其他医疗环境需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic glucocorticoids are recommended for use in chronic obstructive pulmonary disease (COPD) exacerbations; however, there is increased harm associated with their use. We hypothesised that the use of eosinophil biomarker-directed oral prednisolone therapy at the time of an exacerbation of COPD was effective at reducing prednisolone use without affecting adverse outcomes. METHODS: The studying acute exacerbations and response (STARR2) study was a multicentre, randomised, double-blind, placebo-controlled trial conducted in 14 primary care practices in the UK. We included adults (aged ≥40 years), who were current or former smokers (with at least a 10 pack year smoking history) with a diagnosis of COPD, defined as a post-bronchodilator FEV1/forced vital capacity ratio of less than 0·7 previously recorded by the primary care physician, and a history of at least one exacerbation in the previous 12 months requiring systemic corticosteroids with or without antibiotics. All study staff and participants were masked to study group allocation and to treatment allocation. Participants were randomly assigned (1:1) to blood eosinophil-directed treatment (BET; to receive oral prednisolone 30 mg once daily if eosinophil count was high [≥2%] or placebo if eosinophil count was low [<2%]) or to standard care treatment (ST; to receive prednisolone 30 mg once daily irrespective of the point-of-care eosinophil result). Treatment was prescribed for 14 days and all patients also received antibiotics. The primary outcome was the rate of treatment failure, defined as any need for re-treatment with antibiotics or steroids, hospitalisation for any cause, or death, assessed at 30 days after exacerbation in the modified intention-to-treat population. Participants were eligible for re-randomisation at further exacerbations (with a maximum of four exacerbations per participant). A safety analysis was conducted on all randomly assigned participants. Although designed as a superiority trial, after identification of an error in the randomisation code before data lock the study converted to show non-inferiority. An upper margin of 1·105 for the 95% CI was defined as the non-inferiority margin. This study was registered with EudraCT, 2017-001586-24, and is complete. FINDINGS: Between Nov 6, 2017, and April 30, 2020, 308 participants were recruited from 14 general practices. 144 exacerbations (73 in the BET group and 71 in the ST group) from 93 participants (mean age 70 years [range 46-84] and mean percent predicted FEV1 60·9% [SD 19·4]; 52 [56%] male and 41 [44%] female; ethnicity data was not collected]) were included in the modified intention-to-treat analysis. There were 14 (19%) treatment failures at 30 days post-exacerbation in the BET group and 23 (32%) in the ST group; we found a large non-significant estimated effect between BET and ST (RR 0·60 [95% CI 0·33-1·04]; p=0·070) in reducing treatment failures after a COPD exacerbation. The non-inferiority analysis supported that BET was non-inferior to ST. Frequency of adverse events were similar between the study groups; glycosuria (2/102 [2%] in BET group and 1/101 [1%] in the ST group) and hospital admission for COPD exacerbation (2/102 [2%] in BET group and 1/101 [1%] in the ST group) were the two most common adverse events in both groups. No deaths occurred in the study. INTERPRETATION: Blood eosinophil-directed prednisolone therapy at the time of an acute exacerbation of COPD is non-inferior to standard care and can be used to safely reduce systemic glucocorticoid use in clinical practice. FUNDING: National Institute for Health and Care Research.
引用
- Ramakrishnan, Jeffers, Langford-Wiley, et al. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial. Lancet Respir Med. 2023. PMID: 37924830. doi:10.1016/S2213-2600(23)00298-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。